
BIOGRAPHICAL SKETCH

Provide the following information for the key personnel and other significant contributors in the order listed on Form Page 2.
Follow this format for each person. **DO NOT EXCEED FOUR PAGES.**

NAME Yan Gong	POSITION TITLE Research Assistant Professor		
eRA COMMONS USER NAME gongyan			
EDUCATION/TRAINING <i>(Begin with baccalaureate or other initial professional education, such as nursing, and include postdoctoral training.)</i>			
INSTITUTION AND LOCATION	DEGREE <i>(if applicable)</i>	YEAR(s)	FIELD OF STUDY
West China University of Medical Sciences	B.S.	1991-1995	Pharmacy
West China University of Medical Sciences	M.S.	1996-1999	Pharmaceutics
University of Florida	Ph.D	1999-2004	Pharmaceutics
University of Florida	M.S	2001-2003	Statistics
University of Florida	Fellowship	2004-2005	Pharmacogenomics

Positions and Employment

1997-1999 Teaching Assistant, West China University of Medical Sciences School of Pharmacy
1999-2004 Teaching Assistant, University of Florida College of Pharmacy
2005-present Research Assistant Professor, University of Florida College of Pharmacy

Professional Awards and Honors

Travel Award, American Association of Pharmaceutical Scientist, 2003
Oral finalist, Research Showcase, University of Florida College of Pharmacy, 2004
Scholar-in-training Travel Award, Pharmacogenetics Research network, 2005
Best Poster, American Society of Clinical Pharmacology and Therapeutics, 2005
Presidential Trainee Award Winner, American Society for Clinical Pharmacology and Therapeutics, 2006

A. Selected Peer-reviewed Publications

1. Sullivan S, **Gong Y**, and Hughes JA. 2002, Cationic Liposomes in Gene Delivery, Liposomes, A Practical Approach, Second Edition, Oxford University Press, pp: 289-301
2. Klein RL, Hamby ME, **Gong Y**, Hirko AC, Wang S, Hughes JA, King MA, Meyer EM. Dose and promoter effects of adeno-associated viral vector for green fluorescent protein expression in the rat brain. Experimental Neurology 2002; 1: 66-74.
3. **Gong Y**, Chen S, King MA, Hughes JA, Meyer EM. Recombinant Adeno-Associated Virus Serotype 2 Effectively Transduces Primary Rat Brain Astrocytes and Microglia. Brain Research Protocols, 2004; 14: 18-24.
4. **Gong Y**, Zhu Y, Wang Z, Zhao W, Johnson JA, Wu R. A statistical model for functional mapping of quantitative trait loci regulating drug response. Pharmacogenomics J 2004; 4:315-321
5. King MA, **Gong Y**, Meyers C, Hughes JA and Meyer EM, 2004. Localized gene transfer of K670N/M671L app into rat hippocampus produces miniemomic deficits, neuronal degeneration, and alpha7 nicotinic receptor alterations. [abstract] Neurobiology of Aging. 25, S225-S225.
6. **Gong Y**, Meyers C. A., Klein R. L., Meyer E. M., Jeffrey A. Hughes, King M.A. Disposition and Effects of the Human APP695 Swedish Mutation in Rat Brain After rAAV2-Mediated Somatic Gene Transfer. Experimental Neurology 2006; 200(2):371-7
7. **Gong Y**, Beitelshees AL, Stauffer L, Gaston K, Sloan A, Yarandi HN, Langae TY, Cooper-DeHoff RM, Pepine CJ, Johnson JA. Beta 2-adrenergic receptor (B2AR) polymorphisms and antihypertensive response to beta-blocker therapy in the INVEST trial. [abstract] Clin Pharmacol Ther 2005; 2: 22.

8. Beitelshes AL, **Gong Y**, Cooper-DeHoff RM, Moss JI, Pepine CJ, Johnson JA. Variable blood pressure response to verapamil by KCNMB1 genotype. [abstract] Clin Pharmacol Ther 2005; 2: 97.
9. Gerhard T, **Gong Y**, Beitelshes AL, Lobmeyer M, Schiefelbein L, Langae TY, Cooper-DeHoff RM and Johnson JA Association between CV outcomes, diuretic use and the alpha-adducin gene; Results from the International Verapamil SR Trandolapril Study (INVEST). [abstract] Circulation, **112**, U670-U670.
10. **Gong Y**, Beitelshes AL, Stauffer LA, Langae TY, Cooper-DeHoff RM, Pepine CJ, Johnson JA, 2006. Beta adrenergic receptors polymorphisms are associated with response to beta-blocker therapy in the International Verapamil SR-Trandolapril Study (INVEST). [abstract] Clin Pharmacol Ther. 79, 2: 30.
11. Beitelshes AL, **Gong Y**, Cooper-DeHoff RM, Burt L, Stauffer LA, Pepine CJ, Johnson JA. 2006. KCNMB1 genotype associated with cardiovascular outcomes in the International Verapamil SR-Trandolapril Study (INVEST). [abstract] Clin Pharmacol Ther. 79, 2: 41.
12. Brunner M, Karnes JH, **Gong Y**, Langae TY, Cooper-DeHoff RM, Pepine CJ, Johnson JA, 2006. Association of angiotension II type I receptor (AGTR1) 1166A>C polymorphism with blood pressure response to ACE inhibitor in a subgroup of patients of the International Verapamil SR-Trandolapril Study (INVEST). [abstract] Clin Pharmacol Ther. 79, 2: 14.
13. Shin J, Lobmeyer MT, **Gong Y**, Zineh I, Langae TY, Yarandi HN, Pauly DF, Aranda JM, Schofield RS, Hill JA, Johnson JA, 2006. A haplotype of β_2 -adrenoceptor is associated with the increased risk for transplant or death in heart failure patients. [abstract] Clin Pharmacol Ther 79, 2: 30.
14. Lobmeyer MT, Terra SG, **Gong Y**, Hamilton KK, Pauly DF, Patterson JH, Adams KF, Schofield RS, Hill JA, Aranda JM, Johnson JA. 2006. Synergistic polymorphisms of β_1 - and α_{2C} -adrenergic receptors and the influence on left ventricular ejection fraction in response to β -blocker therapy in heart failure. [abstract] Clin Pharmacol Ther. 79, 2: 31.
15. Johnson JA, Karnes JH, Brunner M, **Gong Y**, Langae TY, Cooper-DeHoff RM, Pepine CJ. 2006. Lack of association of the angiotension II type I receptor (AGTR1) 1166 A>C polymorphism with cardiovascular and cerebrovascular outcomes in subgroup of patients of the International Verapamil SR-Trandolapril Study (INVEST). [abstract] Clin Pharmacol Ther. 79, 2: 43.
16. Handberg E, **Gong Y**, DeHoff RC, Ried LD, Pepine CJ. Can an assessment of subjective well being predict outcomes in patients with hypertension and coronary artery disease? A report from the international verapamil-SR/Trandolapril study (INVEST). [abstract] Journal of the American College of Cardiology. Feb 2006; 47(4):300A-300A.
17. **Gong Y**, Beitelshes AL, Wessel J, Langae TY, Schork NJ, Johnson JA. 2007. SNP discovery and haplotype analysis of BK channel beta 1 subunit, , Pharmacogenetics and Genomics, 17(4): 267-275.
18. Shin J, Lobmeyer MT, **Gong Y**, Zineh I, Langae TY, Yarandi H, Schofield RS, Aranda RM Jr., Hill JA., Pauly DF and Julie A. Johnson. 2007. A β_2 -adrenoceptor haplotype is associated with the increased risk for death and heart transplantation in heart failure patients. Am J Cardiol, 99(2):250-5.
19. Lobmeyer MT, **Gong Y**, Terra SG, Beitelshes AL, Langae TY, Pauly DF, Schofield RS, Hamilton KK, Patterson JH, Adams KF, Hill JA, Aranda JM and Johnson JA. 2007. Synergistic polymorphisms of β_1 - and α_{2C} - adrenergic receptors and the influence on left ventricular ejection fraction response to β -blocker therapy in heart failure, Pharmacogenetics and Genomics, 17 (4): 277-282.
20. Langae TY., **Gong Y**, Yarandi H, Katz D, Cooper-DeHoff RM, Pepine CJ, Johnson JA. 2007. Association of CYP3A5 polymorphisms with hypertension and antihypertensive response to verapamil. Clin Pharmacol Ther, 81(3):386.
21. Shin J, Kline S, Moore M, **Gong Y**, Blianderi V, Schmalfuss CM, Schofield RS, Johnson JA. Diurnal blood pressure pattern is associated with risk for hospitalization or death in heart failure. Clinical Pharmacology & Therapeutics. 2007;81:S15-S15
22. Brunner M, Cooper-Dehoff RM, **Gong Y**, Karnes JH, Langae TY, Pepine CJ, Johnson JA. Factors influencing blood pressure response to trandolapril add-on therapy in patients taking verapamil sr (from the international verapamil sr/trandolapril [invest] study). Am J Cardiol. 2007;99:1549-1554
23. Beitelshes AL, **Gong Y**, Wang D, Schork NJ, Cooper-DeHoff RM, Langae TY, Shriver MD, Sadee W, Knot HJ, Pepine CJ, Johnson JA. KCNMB1 genotype influences response to verapamil SR and adverse outcomes in the International Verapamil SR/Trandolapril Study (INVEST). Pharmacogenet Genomics. 2007 Sep;17(9):719-729.

24. Pacanowski MA, **Gong Y**, Langaee TY, Cooper-DeHoff RM, Schork NJ, Pepine CJ, Johnson JA. β_2 -adrenergic receptor polymorphisms and antihypertensive treatment outcomes in the INternational VERapamil SR/ trandolapril STudy – GENetic Substudy (INVEST-GENES). [abstract] *Clin Pharmacol Ther* 2007;81(S1):S34.
25. Shin J, Kline S, Moore M, **Gong Y**, Bhanderi V, Schmalfluss CM, Johnson JA, Schofield RS. Association of diurnal blood pressure pattern with risk of hospitalization or death in men with heart failure. *J Card Fail* 2007;13:656-62.
26. Hassan M, York KM, Li H, Li Q, **Gong Y**, Langaee TY, Fillingim RB, Johnson JA, Sheps DS, Association of beta1-adrenergic receptor genetic polymorphism with mental stress-induced myocardial ischemia in patients with coronary artery disease. *Arch Intern Med*. 2008 Apr 14; 168(7):763-70
27. Gerhard T, **Gong Y**, Beitelshes AL, Lobmeyer MT, Cooper-DeHoff RM, Langaee TY, Schork NJ, Pepine CJ., Johnson JA, for the INVEST Investigators. Association between Cardiovascular Outcomes, Diuretic Therapy and the α -adducin Polymorphism: Results from the INternational VERapamil SR-trandolapril STudy GENetic Substudy (INVEST-GENES). *American Heart Journal*, Aug;156(2):397-40, 2008.
28. Pacanowski MA, **Gong Y**, Cooper-DeHoff, RM, Schork NJ, Shriver, MD, Langaee TY, Pepine CJ, Johnson JA, for the INVEST Investigators. β -adrenergic receptor gene polymorphisms and β -blocker treatment outcomes in hypertension. *Clinical Pharmacology & Therapeutics*. July 9. 2008
29. **Gong Y**, Handberg EM, Gerhard T, Copper-DeHoff RM, Johnson JA. Pepine CJ; for the INVEST investigators. Association of systolic blood pressure and health-related quality of life in patients with CAD: an analysis from the International VERapamil SR-Trandolapril study (INVEST). *Clinical Cardiology*, July 9, 2008.
30. Johnson AD, **Gong Y**, Wang D, Langaee TY, Shin J, Cooper-DeHoff RM, Schork NJ, Binkley P, Pepine CJ, Johnson JA, Sadee W. Promoter Polymorphisms in ACE (angiotension-I converting enzyme) associated with clinical outcomes in hypertension. *Clinical Pharmacology & Therapeutics*, Oct 22. 2008
31. Denardo SJ., Messerli FH, Gaxiola E, Aranda JM, Cooper-DeHoff RM, Handberg EM, **Gong Y**, Champion A, Zhou Q. Pepine CJ. Characteristics and Outcomes of Revascularized Patients with Hypertension: A Substudy of the International Verapamil SR-Trandolapril Study, in press, *Hypertension*, 2009.
32. Johnson JA, Boerwinkle E, Zineh I, Chapman AB, Kailey K, Cooper-DeHoff RM, Gums J, Curry RW, **Gong Y**, Beitelshes AL, Schwartz G, Turner ST. Pharmacogenomics of Antihypertensive drugs: Rationale and Design of the Pharmacogenomic Evaluation of Antihypertensive Responses (PEAR) Study, *American Heart Journal*, in press, 2009
33. Smith SM, Anderson SD, Wen S, Gong Y, Turner ST, Cooper-DeHoff RN, Schwartz GL, Bailey K, Chapman A, Hall KL, Feng H, Boerwinkle E, Johnson JA, Gums JG. Thiazide-induced Hyperglycemia is not related to hypokalemia: results from the Pharmacogenomic Evaluation of Antihypertensive Response (PEAR) Study, *Pharmacotherapy*, in press, 2009
34. Johnson JA, **Gong Y**, Bailey KR, Cooper-DeHoff RM, Chapman AB, Turner ST, Schwartz GL, Campbell K, Schmidt Siegfried, Beitelshes AL, Boerwinkle E, Gums JG. Combination antihypertensive therapy with hydrochlorothiazide and atenolol: effect of initiation order. *Clinical Pharmacology and Therapeutics*, in press, 2009
35. Beitelshes AL, Navare H, Wang D, **Gong Y**, Wessel J, Moss JI, Langaee TY, Cooper-DeHoff RM, Sadee W, Pepine CJ, Schork NJ, Johnson JA. *CACNA1C* gene polymorphisms, cardiovascular disease outcomes and treatment response, *Circulation Cardiovascular Genetics*, in press, 2009
36. Niu Y, Langaee TY, **Gong Y**, Moss JI, Beitelshes AL, Cooper-DeHoff RM, Pepine CJ, Johnson JA. DNA variations in the voltage-gated calcium channel beta 2 subunit (*CACNB2*) gene and their association with adverse cardiovascular outcomes in the INternational VERapamil SR-trandolapril STudy-GENetic Substudy (INVEST-GENES), submitted, 2009
37. **Gong Y**, Handberg EM, Copper-DeHoff RM, Matyas K, Johnson JA., Pepine CJ; for the INVEST investigators. Office vs Ambulatory Blood Pressure in Hypertensive CAD Patients: Findings from the INternational VERapamil SR - Trandolapril STudy (INVEST). Submitted, 2009
38. Cooper-DeHoff RM, Wen Sheron, Beitelshes AL, Zineh I, Gums JG, Turner ST, **Gong Y**, Hall K, Parekh V, Chapman A, Boerwinkle E, Johnson JA. Impact of Abdominal Obesity on Incidence of Adverse Metabolic Effects Associated with Antihypertensive Medications. Submitted, 2009
39. Beitelshes AL, **Gong Y**, Bailey KR, Turner ST, Chapman AB, Schwartz GL, Gums JG, Boerwinkle E, Johnson JA. Comparison of Office, Ambulatory, and Home Blood

Pressure Antihypertensive Response to Atenolol and Hydrochlorothiazide. Submitted, 2009

C. Research Support

R01 HL074730 (PI: J.A. Johnson) September 2003- August 2007

NIH/NHLBI

“Hypertension pharmacogenetics”

The aims of this study are to: 1) Determine SNPs in five genes relevant to calcium regulation and the calcium channel blocker response; 2) Determine *in vitro* functional consequences of discovered polymorphisms; 3) Determine association between sequence variability in relevant genes and antihypertensive response to verapamil; 4) Determine associations between genotype and outcomes (death, myocardial infarction, stroke) for patients taking atenolol, verapamil, trandolapril and hydrochlorothiazide; 5) Determine the role of assessing population stratification and ancestral proportions using genetic markers in pharmacogenetic studies.

Role: Co-investigator

U01 GM074492 (PI: J.A. Johnson) September 2003 – August 2009

NIH/NIGMS

“Pharmacogenomic Evaluation of Antihypertensive Response (PEAR)”

The aims of this study are to: identify genetic predictors of the antihypertensive and adverse metabolic responses to a β -blocker (atenolol) and a thiazide diuretics (HCTZ), first by testing 7 SNPs in each of 70 candidate genes for genetic association with: antihypertensive responses to monotherapy (Aim 1a), addition of a second drug to monotherapy (Aim 1b), and combination therapy (Aim 1c); and adverse metabolic responses to mono and combination therapy (Aim 1d). Aim 2 seeks to identify genetic associations with these same responses through testing of 20,000 putative functional SNPs that span the human genome.

Role: co-investigator

R-238 (PI: Dr. Joseph Katz) September 2008 - September 2010

Micromedic Technologies

“Pharmacogenetics, pharmacokinetics and bone markers

Pharmacogenomics study of Bisphosphonate-Associated Osteonecrosis of the Jaw (BONJ) “

Role: co-investigator